[smartslider3 slider=2]

Phelix goals

Phelix studies chronic infections and bacteriophages. Our first development will allow a diagnostic method, prevention methods and innovative treatments for Lyme disease. Our goal is to apply this knowledge to fight infectious diseases suspected of being responsible for the most common neurodegenerative diseases.


With the expansive knowledge from the entire global community of scientists available to us in the form of research papers, we are able to identify current issues in the related field and draw links between particular problems to consider new models of infectious disease.


Currently, we are focussed on supporting research surrounding bacteriophages and their potential uses in chronic infection.
However, we are constantly looking for new ways to understand neurodegenerative diseases.


We are working on developing a new diagnostic method to test for Borrelia spp. in those suspected of carrying the bacteria.
It is a bacteriophage-based test of the patient’s blood or urine, which has improved sensitivity and specificity.

We need you

Phelix relies entirely on donations to fund a range of research projects on Lyme disease, its diagnosis and its treatment by specific bacteriophages. This research and these same strategies will also serve another great cause: the identification of infections involved in the onset and morbidity of serious neurodegenerative diseases, particularly autism spectrum disorders. 100% of your donations go to research, as our team is made up of volunteers.

Continue reading “Donate”

Our Ambitions

About neurodegenerative conditions

More and more clinical and medical evidence indicates that many neurodegenerative diseases (Autism Spectrum Disorder and Alzheimer’s Disease, most relevantly) have infectious origins. The development of a more sensitive and specific diagnostic test would be a game changer in the way we diagnose, treat and prevent these conditions.

About bacteriophages

As antibiotic resistance increases and the number of new antibiotics being brought to the market decreases, the use of bacteriophages as an alternative to antibiotics and a novel therapeutic for infectious disease, either through the use of lytic phages or phage-encoded enzymes, seems increasingly attractive.

About chronic infections

Currently, there is no standardised method of investigation into infectious disease in chronic conditions. We aim to generalise our phage-based test to other pathogens to investigate the epigenetic implication of infection in chronic conditions.